Comparison of Two High-Throughput Reverse Transcription-PCR Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2

@article{Craney2020ComparisonOT,
  title={Comparison of Two High-Throughput Reverse Transcription-PCR Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2},
  author={Arryn Craney and Priya D. Velu and Michael J. Satlin and Kathy A. Fauntleroy and Katrina Callan and Amy E. Robertson and Marisa La Spina and Beryl Lei and Anqi Chen and Tricia Alston and Anna Rozman and Massimo Loda and Hanna Rennert and Melissa M. Cushing and Lars F Westblade},
  journal={Journal of Clinical Microbiology},
  year={2020},
  volume={58}
}
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as the cause of a worldwide pandemic. Many commercial SARS-CoV-2 reverse transcription-PCR (RT-PCR) assays have received Emergency Use Authorization from the U.S. Food and Drug Administration. However, there are limited data describing their performance, in particular the performance of high-throughput SARS-CoV-2 RT-PCR systems. We analyzed the diagnostic performance of two high-throughput systems: cobas 6800 and Panther… 

Performance Characteristics of a High-Throughput Automated Transcription-Mediated Amplification Test for SARS-CoV-2 Detection

TLDR
A new, high-throughput, fully automated nucleic acid amplification test system for the detection of SARS-CoV-2 RNA and its results provide validation evidence for a sensitive and specific method for pandemic-scale automated molecular diagnostic testing for Sars-CoVs.

Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study

TLDR
The Liat is an RT-PCR POC test that provides highly accurate SARS-CoV-2 results in 20 min with performance equivalent to that of high-throughput laboratory molecular testing.

Laboratory tests for the detection of SARS-CoV-2 infection: basic principles and examples

  • K. Alkharsah
  • Biology, Medicine
    German medical science : GMS e-journal
  • 2021
TLDR
This review summarizes the principles of the available laboratory assays that are in use for the detection of SARS-CoV-2 RNA, antigens, or antibodies.

Molecular detections of coronavirus: current and emerging methodologies

TLDR
This review summarized the current knowledge of established and emerging methods for coronavirus detection and the characteristics of different diagnostic approaches were described, and the strengths and weaknesses of each method were analyzed and compared.

Diagnostic accuracy for a plasma SARS-CoV-2 Nucleocapsid Protein method

TLDR
The NP method is acceptable for making the laboratory diagnosis of SARS-CoV-2, and an intended use of plasma NP as a prospective nosocomial screening method is considered feasible.

Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2

TLDR
A multiplatform testing approach is proposed, depending on patient population and assay sensitivity, to address testing needs during a public health emergency.

Distribution of SARS-CoV-2 PCR Cycle Threshold Values Provide Practical Insight Into Overall and Target-Specific Sensitivity Among Symptomatic Patients

TLDR
Based on the distribution of observed CT values, including the small proportion of specimens with values near the assay LoD, there is a low risk of false-negative RT-PCR results in combined nasopharyngeal-oropharynGEal specimens obtained from symptomatic individuals.

An Overview of SARS-CoV-2 Molecular Diagnostics in Europe

Commercial SARS-CoV-2 Molecular Assays: Superior Analytical Sensitivity of cobas SARS-CoV-2 Relative to NxTAG Cov Extended Panel and ID NOW COVID-19 Test.

TLDR
Clinical specimens exhibit a wide range of viral burden, with a significant portion at low levels, which is critical for reliable detection of SARS-CoV-2 and uniform care to patients.

Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Test

TLDR
The Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV test showed high sensitivity and accuracy for all analytes included in the test, and will provide a valuable clinical diagnostic and public health solution for detecting and differentiating SAR's coronavirus 2, influenza A and B virus, and RSV infections during the current respiratory virus season.

References

SHOWING 1-10 OF 16 REFERENCES

Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2

TLDR
A multiplatform testing approach is proposed, depending on patient population and assay sensitivity, to address testing needs during a public health emergency.

Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of Diagnostic Testing for SARS–CoV-2/COVID-19

TLDR
The types of tests available and how they might be useful in the face of a rapidly changing and never-before-experienced situation are explained.

Detection of SARS-CoV-2 by Use of the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays

SARS-CoV-2, a novel coronavirus responsible for a December 2019 outbreak in Wuhan, China, causes a syndrome characterized by fever, cough, and dyspnea progressing to acute respiratory distress

Comparison of Abbott ID Now and Abbott m2000 Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Symptomatic Patients

TLDR
The ID NOW COVID-19 (IDNCOV) assay performed on the ID Now Instrument is a rapid diagnostic test that can be performed in a point of care setting equivalent to CLIA waived testing.

Interrater reliability: the kappa statistic

TLDR
While the kappa is one of the most commonly used statistics to test interrater reliability, it has limitations and levels for both kappa and percent agreement that should be demanded in healthcare studies are suggested.

Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Individuals Diagnosed with COVID-19

Dozens of in vitro diagnostics (IVDs) have received emergency use authorization (EUA) from the U.S. Food & Drug Administration (FDA) for the detection of SARS-CoV-2, but little has been studied to

Xpert Xpress SARS-CoV-2 EUA assay package insert v1.0

    cobas SARS-CoV-2 EUA assay package insert v1.0

    • 2020

    and Drug Administration

    • 2020. Emergency use authorizations. https://www.fda.gov/medical-devices/emergency-situations-medical -devices/emergency-use-authorizations#covid19ivd. Accessed 20 April
    • 2020